The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03463-9

Hajnalka Szaboki, Jonathan L. Kaufman, Shambavi Richard, Sebastian Grosicki, Istvan Takacs, Marc Raab, Cyrus Khandanpour, Andras Strassz, Andreas Pahl, Michael Kulke, Kristin Decker, Alexandra Braun, Thomas Philippi, Anette Last, Clemens Kruspel, Robert Orlowski, Frank Richard, Oliver Schonborn-Kellenberger, Throsten Lehr, Christiane Dings

引用次数: 0

查看原文本刊更多论文

抗bcma抗体-药物偶联HDP-101与一种新的Amanitin有效载荷在复发/难治性多发性骨髓瘤的1/2a期临床试验中显示出有希望的数据，并进入队列7

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.